Abstract: The present invention relates to a method of preparing a solid form of soy isoflavone (e.g. genistein). In particular, the present invention relates to a method of preparing a solid form of soy isoflavone by precipitation with compressed antisolvent using a supercritical fluid to produce nano-sized particles of soy isoflavone with an improved dissolution rate and bioavailability. An oral composition or aerosolized formulation comprising the nanoparticles of the soy isoflavone prepared by the method of the present invention is also disclosed herein. The dissolution rate and bioavailability of the nanoparticles of the soy isoflavone prepared by the method of the present invention have a 2-fold increase and a 2.6-fold increase respectively as compared to those of the raw soy isoflavone.

Abstract: The present invention relates to the use of a compound of Formula I for the manufacture of a medicament for treating or preventing cancer in a subject.

Abstract: The present invention relates to the use of a compound of Formula I for the manufacture of a medicament for treating or preventing cancer in a subject.

Abstract: A novel compound isolated from the plant Garcinia paucinervis. The compound's structure is as follows: The compound possesses a potent ability to activate caspase-3 in HeLa-C3 cells within 72 h at a low concentration of 25 ?M. The IC50 on HeLa cells for this compound was measured to be below 10 ?M, indicating a strong HeLa cell growth inhibitory effect.

Abstract: Novel polyisoprenylated benzophenone derivatives isolated from the plant Garcinia paucinervis. Among these new compounds, paucinones A-C (Compounds 1-3) contains an unexpected cyclohexane-spiro-tetrahydrofuran moiety. A 1-methylene-3,3-dimethylcyclohexane group never reported before was found in the structure of paucinone D (Compound 4). Structures of these compounds were elucidated with spectroscopic evidence. The relative stereochemistry of 1-4 was determined by NOESY correlations. These compounds a potent ability to activate caspase-3 in HeLa-C3 cells within 72 hours at a low concentration and significant cytotoxicity against HeLa-C3 cells.